Key result
ACEi and ARBs eliminate angiotensin II-induced inflammation and lung fibrosis in COVID-19.
Why the study?
The role of angiotensin II in COVID-19 pathophysiology and the potential therapeutic effects of ACEi and ARB drugs were explored.
Do ACEi and ARB drugs reduce the inflammatory response and lung fibrosis in COVID-19?
Do ACEi and ARB drugs reduce the inflammatory response and lung fibrosis in COVID-19?
This paper hypothesizes that ACE inhibitors and ARBs may be beneficial in COVID-19 by counteracting the harmful inflammatory and fibrotic effects of elevated Angiotensin II.
Answers are grounded in this paper and cite their sources.
Does not support altering ACEi/ARB therapy in COVID-19; leaves open mechanistic role of ACE2-angiotensin axis in lung injury.
• Binding of the SARS-CoV-2 to ACE2 causes its endocytosis. • Decreased ACE2 at the cell surface causes increase angiotensin II levels. • High Angiotensin II levels induce the inflammatory response and lung fibrosis. • ACEi and ARB drugs eliminate the harmful effects of the angiotensin II.
No takes yet. Share an insight, caveat, or question.
Khezri et al. (2021) studied this question. ACE inhibitors and ARBs eliminate the harmful inflammatory response and lung fibrosis induced by elevated angiotensin II levels in COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: